1-3 of 3
Hartmut Doehner, MD, PhD
Close
Sort by
Journal Articles

Efficacy Analysis of the Novel Dual PI3K-MTORC1/2 Inhibitors NVP-BGT226 and NVP-BEZ235 in Acute Leukemia.

Marcus M Schittenhelm, Dr., MD, Hartmut Doehner, MD, PhD, Konstanze Doehner, Lothar Kanz, MD, Michael C. Heinrich, MD, Kerstin M Kampa-Schittenhelm, Dr., MD
Journal: Blood
Blood (2012) 120 (21): 2474.
https://doi.org/10.1182/blood.V120.21.2474.2474
Published: 2012
Journal Articles

Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine

Gesine Bug, MD, PhD, Richard F. Schlenk, MD, PhD, Carsten Müller-Tidow, MD, PhD, Michael Lübbert, MD, PhD, Alwin Krämer, MD, PhD, Frank Fleischer, Tillmann Taube, MD, Oliver G. Ottmann, MD, PhD, Hartmut Doehner, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3316.
https://doi.org/10.1182/blood.V116.21.3316.3316
Published: 2010
Journal Articles

Association of Elevated Circulating Proteasome Levels at Diagnosis with Poor Outcome in Multiple Myeloma

Peter Liebisch, MD, Stephan Sixt, MD, Hagen S Bachmann, MD, Ulrich H Frey, MD, Juergen Peters, MD, Hartmut Doehner, MD, PhD, Ulrich Duehrsen, MD, Holger Nückel, MD
Journal: Blood
Blood (2008) 112 (11): 5140.
https://doi.org/10.1182/blood.V112.11.5140.5140
Published: 2008